Improving care for polycythemia vera patients
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how doctors document and assess polycythemia vera (PV) care. It aims to improve record-keeping and treatment for patients with PV.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be a hematologist or medical oncologist at a Mass General Brigham site.
- Treat at least one patient with polycythemia vera (PV) in your clinic.
- Use the EPIC electronic medical record (EMR) system.
- Have an outpatient clinic at Mass General Brigham.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study watches how a blood condition called essential thrombocythemia (ET) changes into another condition called polycythemia vera (PV) in people with a specific JAK2 mutation. It aims to learn more about these changes and what happens to patients over time.
This trial tests a new drug called 9MW3011 for people with polycythemia vera (PV) who haven't done well on or can't take standard treatments like hydroxyurea or interferon. The goal is to see if the drug is safe and how it works in your body.
This is an observational study that follows people with certain blood disorders. It aims to learn more about how these conditions behave in real life, which can help improve future care.
This observational registry tracks symptoms, treatments, and disease changes over time in people diagnosed with myeloproliferative neoplasms (MPNs). By joining, you help doctors learn more about the condition and possibly contribute to better future care.
This study tests an injection called BEBT-507 for people with polycythemia vera (a blood condition that makes too many red blood cells). It's for those who haven't responded well to or can't tolerate standard treatments like hydroxyurea or interferon. The goal is to see if this new drug can help control the disease.
This study compares a new drug called givinostat to hydroxyurea (a standard treatment) for people with polycythemia vera, a blood disorder that increases the risk of clots. The goal is to see if givinostat works better and is safe.
Hear when a new Polycythemia Vera trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.